<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090607</url>
  </required_header>
  <id_info>
    <org_study_id>NECTAR</org_study_id>
    <nct_id>NCT03090607</nct_id>
  </id_info>
  <brief_title>Novel Endoluminal Clinical TreAtment of Reflux</brief_title>
  <acronym>NECTAR</acronym>
  <official_title>A 12-month Double-blind, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Efficacy of Endoluminal Aluvra™ for the Treatment of Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impleo Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impleo Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, double-blind randomized controlled trial designed to
      demonstrate the safety and efficacy of Aluvra for the treatment of GERD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Aluvra- GERD HRQL</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy will be established through two co-primary objectives. The first co-primary endpoint will be to compare response rates between treatment group and control group at 12 months based on the GERD-Health Related Quality of Life questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Aluvra- Esophageal PH</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy will be established through two co-primary objectives. The second co-primary endpoint will be to compare change from baseline in total percent time esophageal pH &lt;4 between the treatment group vs. the sham control group at 12 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Aluvra™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Endoscopic injection of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aluvra™</intervention_name>
    <description>Endoscopic injection of bulking agent to the lower esophageal sphincter</description>
    <arm_group_label>Aluvra™</arm_group_label>
    <other_name>injectable bulking agent for GERD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Endoscopic injection of saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of heartburn-like pain, regurgitation, or both prior to the initiation of
             proton pump inhibitor (PPIs) therapy.

          2. History of GERD symptoms of at least six months despite continuous PPIs.

          3. GERD-HRQL score ≥15 after discontinuing PPI therapy.

          4. GERD-HRQL score improvement of at least 6 points while on PPIs, with at least 4-point
             improvement in heartburn subscore.

          5. A minimum GERD-HRQL score while on PPIs of 2.

          6. Pathologic acid exposure time, a baseline pH &lt;4.0 for ≥ 5.3% of time during a 48-hour
             evaluation period.

          7. Twenty two years of age or older.

          8. Life expectancy of at least two years.

          9. Willing and able to return to the clinic or hospital for all evaluation procedures
             scheduled throughout the course of this study.

         10. Is capable of understanding clinical study procedures and giving informed consent.

        Exclusion Criteria:

          1. Unable to tolerate an endoscopic procedure

          2. Presence of esophageal or gastric varices

          3. Presence of erosive esophagitis (LA Classification of C or D)

          4. Presence of a hiatal hernia &gt; 2 cm

          5. Presence of Barrett's esophagus

          6. Presence of esophageal motility disorder

          7. History of or known esophageal stricture or gross esophageal anatomic abnormalities

          8. Symptoms of dysphagia more than once per week within the last six months

          9. Obesity (BMI ≥ 35)

         10. Gastric or esophageal cancer undergoing active treatment

         11. Received radiation therapy to the esophagus and has fibrosis of the tissue at the
             likely injection sites

         12. Had an ablation procedure in the lower esophageal sphincter area

         13. Has a condition that could lead to significant postoperative complications, including
             current infection, anticoagulant use, uncontrolled diabetes or autoimmune disorder

         14. Enrolled in a concurrent clinical trial

         15. Inability to comply with study protocol due to a chronic disease, psychiatric illness,
             alcoholism, drug abuse, or geographic distance (as determined by investigator)

         16. Pregnant and/or given birth in the previous twelve months or who plan to become
             pregnant in the next twelve months

         17. Prior gastric or GERD surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>sharona segal-leibovich</last_name>
    <phone>6128453667</phone>
    <email>ssegal@impleomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana Elstad</last_name>
    <email>jelstad@impleomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Digestive Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Pathak</last_name>
      <phone>650-721-8437</phone>
      <email>Divya22@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOFI - Center for Esophageal Wellness</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Heidrick</last_name>
      <phone>303-788-1636</phone>
      <email>rachel@sofisite.com</email>
    </contact>
    <investigator>
      <last_name>Reginald Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Hofbauer,</last_name>
      <phone>617-677-4046</phone>
      <email>mhofbaue@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Pleskow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Nix</last_name>
      <phone>314-362-3201</phone>
      <email>nixd@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash C Gyawali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Center Summit</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Ciezki</last_name>
      <phone>414-649-7173</phone>
      <email>kristin.ciezki@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Nimish Vakil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

